ARWR
Arrowhead Pharmaceuticals, Inc.
$72.69
-6.75%
2026-05-08
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Key Fundamentals
P/E Ratio
46.42
Forward P/E
-17.36
EPS (TTM)
$1.60
ROE
75.5%
Revenue Growth (YoY)
10461.3%
Profit Margin
18.5%
Debt/Equity
124.07
Price/Book
17.95
Beta
1.29
Market Cap
$10.40B
Avg Volume (10D)
1.5M
Recent Breakout Signals
No recent breakout signals detected for ARWR.
Recent Price Range (60 Days)
60D High
$79.48
60D Low
$54.02
Avg Volume
2.0M
Latest Close
$72.69
Get breakout alerts for ARWR
Sign up for Breakout Scanner to receive daily notifications when ARWR triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Arrowhead Pharmaceuticals, Inc. (ARWR) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ARWR daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ARWR operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.